MedTrace Logo

Study of ABO2102 in KRAS-Mutated Solid Tumors

NCT07455617 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2026-04-06

No results posted yet for this study

Summary

This is a multicenter, open-label Phase 1 clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, as well as preliminary anti-tumor activity of ABO2102 as monotherapy and in combination among participants with solid tumors with KRAS mutations.

Conditions

  • Advanced / Metastatic Solid Tumor

Interventions

DRUG

ABO2102 Injection

mRNA encoding mutant KRAS neoantigens, administrated intramuscularly

DRUG

Sintilimab injection

Anti-PD-1 antibody, administered intravenously

Sponsors & Collaborators

  • Abogen Biosciences (Shanghai) Co., Ltd

    collaborator INDUSTRY

  • Suzhou Abogen Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-24
Primary Completion
2029-06-30
Completion
2030-02-28
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07455617 on ClinicalTrials.gov